Fingolimod reduces recurrence of disease activity after natalizumab withdrawal in multiple sclerosis

Journal of Neurology

Volumn 260, Issue 5, 2013, Pages 1382-1387

  Havla, Joachim ^a   Tackenberg, Björn ^b   Hellwig, Kerstin ^c   Meinl, Ingrid ^a   Krumbholz, Markus ^a   Seitz, Florian ^b   Eienbröker, Christian ^b   Gold, Ralf ^c   Hohlfeld, Reinhard ^a   Kleiter, Ingo ^c   Kümpfel, Tania ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b PHILIPPS UNIVERSITY MARBURG   (Germany)

^c ST JOSEF HOSPITAL   (Germany)

Author keywords

Disease activity; Fingolimod; Multiple sclerosis; Natalizumab discontinuation

Indexed keywords

DRUG DERIVATIVE; FINGOLIMOD; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY; NATALIZUMAB; PROPANEDIOL DERIVATIVE; SPHINGOSINE;

ADULT; ARTICLE; DISABILITY; DRUG SUBSTITUTION; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; TIME; YOUNG ADULT; ANALOGS AND DERIVATIVES; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; DISABILITY EVALUATION; DRUG SUBSTITUTION; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PROPYLENE GLYCOLS; SPHINGOSINE; TIME FACTORS; YOUNG ADULT;

EID: 84885751286     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-012-6808-8     Document Type: Article

References (13)

1. Bloomgren G, Richman S, Hotermans C, Subramanyam M, Goelz S, Natarajan A, Lee S, Plavina T, Scanlon JV, Sandrock A, Bozic C (2012) Risk of natalizumab-associated progressive multifocal leukoencephalopathy. NEJM 366:1870-1880.
2. Daelman L, Maitrot A, Maarouf A, Chaunu M, Papeix C, Tourbah A (2012) Severe multiple sclerosis reactivation under fingolimod 3 months after natalizumab withdrawal. Mult Scler 18:1647-1649.
3. Gorelik L, Lerner M, Bixler S, Crossman M, Schlain B, Simon K, Pace A, Cheung A, Chen LL, Berman M, Zein F, Wilson E, Yednock T, Sandrock A, Goelz SE, Subramanyam M (2010) Anti-JC virus antibodies: implications for PML risk stratification. Ann Neurol 68:295-303.
4. Havla J, Gerdes LA, Meinl I, Krumbholz M, Faber H, Weber F, Pellkofer HL, Hohlfeld R, Kumpfel T (2011) De-escalation from natalizumab in multiple sclerosis: recurrence of disease activity despite switching to glatiramer acetate. J Neurol 258:1665-1669.
5. Kappos L, Bates D, Edan G, Eraksoy M, Garcia-Merino A, Grigoriadis N, Hartung HP, Havrdova E, Hillert J, Hohlfeld R, Kremenchutzky M, Lyon-Caen O, Miller A, Pozzilli C, Ravnborg M, Saida T, Sindic C, Vass K, Clifford DB, Hauser S, Major EO, OConnor PW, Weiner HL, Clanet M, Gold R, Hirsch HH, Radu EW, Sorensen PS, King J (2011) Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol 10:745-758.
6. Killestein J, Vennegoor A, Strijbis EM, Seewann A, van Oosten BW, Uitdehaag BM, Polman CH (2010) Natalizumab drug holiday in multiple sclerosis: poorly tolerated. Ann Neurol 68:392-395.
7. Magraner MJ, Coret F, Navarre A, Bosca I, Simo M, Escutia M, Bernad A, Navarro L, Casanova B (2011) Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: A prospective, 6-month observational study. J Neurol 258:1805-1811.
8. OConnor PW, Goodman A, Kappos L, Lublin FD, Miller DH, Polman C, Rudick RA, Aschenbach W, Lucas N (2011) Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology 76:1858-1865.
9. Polman CH, OConnor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, Phillips JT, Lublin FD, Giovannoni G, Wajgt A, Toal M, Lynn F, Panzara MA, Sandrock AW (2006) A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. NEJM 354:899-910.
10. Rigau V, Mania A, Befort P, Carlander B, Jonquet O, Lassmann H, Camu W, Thouvenot E (2012) Lethal multiple sclerosis relapse after natalizumab withdrawal. Neurology, published online before print October 24, 2012. doi:10.1212/WNL.0b013 e318275979d.
11. Rinaldi F, Seppi D, Calabrese M, Perini P, Gallo P (2012) Switching therapy from natalizumab to fingolimod in relapsing-remitting multiple sclerosis: clinical and magnetic resonance imaging findings. Mult Scler 18:1640-1643.
12. Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue EW, Lublin FD, Weinstock-Guttman B, Wynn DR, Lynn F, Panzara MA, Sandrock AW (2006) Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. NEJM 354:911-923.
13. Stuve O, Cravens PD, Frohman EM, Phillips JT, Remington GM, von Geldern G, Cepok S, Singh MP, Cohen Tervaert JW, De Baets M, MacManus D, Miller DH, Radu EW, Cameron EM, Monson NL, Zhang S, Kim R, Hemmer B, Racke MK (2009) Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy. Neurology 72:396-401.